Pemetrexed had significantly better clinical efficacy in patients with stage IV lung adenocarcinoma with susceptible EGFR mutations receiving platinum-based …
CJ Yang, MJ Tsai, JY Hung, TC Liu… - OncoTargets and …, 2016 - Taylor & Francis
Background Increased evidences show that epidermal growth factor receptor (EGFR)-
tyrosine kinase inhibitors such as gefitinib could prolong progression-free survival (PFS) …
tyrosine kinase inhibitors such as gefitinib could prolong progression-free survival (PFS) …
Pemetrexed had significantly better clinical efficacy in patients with stage IV lung adenocarcinoma with susceptible EGFR mutations receiving platinum-based …
CJ Yang, MJ Tsai, JY Hung, TC Liu… - OncoTargets and …, 2016 - dovepress.com
Background: Increased evidences show that epidermal growth factor receptor (EGFR)-
tyrosine kinase inhibitors such as gefitinib could prolong progression-free survival (PFS) …
tyrosine kinase inhibitors such as gefitinib could prolong progression-free survival (PFS) …
[引用][C] Pemetrexed had significantly better clinical efficacy in patients with stage IV lung adenocarcinoma with susceptible EGFR mutations receiving platinum-based …
CJ Yang, IW Chong, MJ Tsai, JY Hung… - OncoTargets and …, 2016 - cir.nii.ac.jp
Pemetrexed had significantly better clinical efficacy in patients with stage IV lung
adenocarcinoma with susceptible EGFR mutations receiving platinum-based chemotherapy after …
adenocarcinoma with susceptible EGFR mutations receiving platinum-based chemotherapy after …
[HTML][HTML] Pemetrexed had significantly better clinical efficacy in patients with stage IV lung adenocarcinoma with susceptible EGFR mutations receiving platinum-based …
CJ Yang, MJ Tsai, JY Hung, TC Liu… - OncoTargets and …, 2016 - ncbi.nlm.nih.gov
Background Increased evidences show that epidermal growth factor receptor (EGFR)-
tyrosine kinase inhibitors such as gefitinib could prolong progression-free survival (PFS) …
tyrosine kinase inhibitors such as gefitinib could prolong progression-free survival (PFS) …
Pemetrexed had significantly better clinical efficacy in patients with stage IV lung adenocarcinoma with susceptible EGFR mutations receiving platinum-based …
CJ Yang, MJ Tsai, JY Hung, TC Liu… - OncoTargets & …, 2016 - search.ebscohost.com
Background: Increased evidences show that epidermal growth factor receptor (EGFR)-
tyrosine kinase inhibitors such as gefitinib could prolong progression-free survival (PFS) …
tyrosine kinase inhibitors such as gefitinib could prolong progression-free survival (PFS) …
Pemetrexed had significantly better clinical efficacy in patients with stage IV lung adenocarcinoma with susceptible EGFR mutations receiving platinum-based …
CJ Yang, MJ Tsai, H Jen-Yu, TC Liu… - OncoTargets and …, 2016 - search.proquest.com
Background: Increased evidences show that epidermal growth factor receptor (EGFR)-
tyrosine kinase inhibitors such as gefitinib could prolong progression-free survival (PFS) …
tyrosine kinase inhibitors such as gefitinib could prolong progression-free survival (PFS) …
Pemetrexed had significantly better clinical efficacy in patients with stage IV lung adenocarcinoma with susceptible EGFR mutations receiving platinum-based …
CJ Yang, MJ Tsai, JY Hung, TC Liu, SH Chou… - OncoTargets and …, 2016 - go.gale.com
Background: Increased evidences show that epidermal growth factor receptor (EGFR)-
tyrosine kinase inhibitors such as gefitinib could prolong progression-free survival (PFS) …
tyrosine kinase inhibitors such as gefitinib could prolong progression-free survival (PFS) …
Pemetrexed had significantly better clinical efficacy in patients with stage IV lung adenocarcinoma with susceptible EGFR mutations receiving platinum-based …
CJ Yang, MJ Tsai, JY Hung, TC Liu… - Oncotargets and …, 2016 - europepmc.org
Background Increased evidences show that epidermal growth factor receptor (EGFR)-
tyrosine kinase inhibitors such as gefitinib could prolong progression-free survival (PFS) …
tyrosine kinase inhibitors such as gefitinib could prolong progression-free survival (PFS) …
Pemetrexed had significantly better clinical efficacy in patients with stage IV lung adenocarcinoma with susceptible EGFR mutations receiving platinum-based …
CJ Yang, MJ Tsai, JY Hung, TC Liu… - OncoTargets and …, 2016 - pubmed.ncbi.nlm.nih.gov
Background Increased evidences show that epidermal growth factor receptor (EGFR)-
tyrosine kinase inhibitors such as gefitinib could prolong progression-free survival (PFS) …
tyrosine kinase inhibitors such as gefitinib could prolong progression-free survival (PFS) …
Pemetrexed had significantly better clinical efficacy in patients with stage IV lung adenocarcinoma with susceptible EGFR mutations receiving platinum-based …
CJ Yang, MJ Tsai, JY Hung, TC Liu… - Oncotargets and …, 2016 - europepmc.org
Background Increased evidences show that epidermal growth factor receptor (EGFR)-
tyrosine kinase inhibitors such as gefitinib could prolong progression-free survival (PFS) …
tyrosine kinase inhibitors such as gefitinib could prolong progression-free survival (PFS) …